|
APIs for Parkinson’s Disease
Products No.: | IC-01-01001 | Products Name: | (4aR,10bR)-4-propyl-2,3,4,4a,5,10b-hexahydrochromeno[4,3-b][1,4]oxazin-9-ol hydrochloride | Synonyms: | (+)PD 128907 | Cas No.: | 300576-59-4;123594-64-9 | Molecular Formula: | C14H20ClNO3 | Molecular Weight: | 285.77 | Assay | 化学纯:HPLC 98%; 光学纯:chiral HPLC 97% | Package | 10g;50g;250g;500g;1kg;5kg;25kg | Molecular Structure: | | Off white powder. Important active leading compound for Parkinson’s disease,PD. |
Products No.: | IC-01-01002 | Products Name: | Rasagiline mesylate | Synonyms: | (1R)-2,3-Dihydro-N-2-propyn-1-yl-1H-inden-1-amine Mesylate;TVP-101;Agilect | Cas No.: | 161735-79-1 | Molecular Formula: | C13H17NO3S | Molecular Weight: | 267.34 | Assay | 98% | Package | 5g;25g;100g;250g;1kg;5kg | Molecular Structure: | | A selective irreversible MAO-B inhibitor. Antiparkinsonian. White to Off-White Crystalline Solid, m.p.:155-158°C |
Products No.: | IC-01-01003 | Products Name: | 1-AMINOINDANE HYDROCHLORIDE | Synonyms: | 2,3-Dihydro-1H-inden-1-amine hydrochloride | Cas No.: | 70146-15-5 | Molecular Formula: | C9H12ClN | Molecular Weight: | 169.65 | Assay | 98% | Package | 5g;25g;100g;250g;1kg;5kg | Molecular Structure: | | Key Intermediates for API rasagiline. |
Products No.: | IC-01-01004 | Products Name: | (R)-2,3-dihydro-1H-inden-1-amine hydrochloride | Synonyms: | R-(-)-1-Aminoindan hydrochloride salt | Cas No.: | 10305-73-4 | Molecular Formula: | C9H12ClN | Molecular Weight: | 169.65 | Assay | 98% | Package | 25g;100g;500g;1kg;5kg;25kg | Molecular Structure: | | m.p.:232-234℃,white powder, as the key intermediate for rasagiline mesylate, the new APIs for Parkinson's disease. |
Products No.: | IC-01-01006 | Products Name: | Rivastigmine | Synonyms: | 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate | Cas No.: | 123441-03-2 | Molecular Formula: | C14H22N2O2 | Molecular Weight: | 250.34 | Assay | 99% | Package | 25g;100g;500g;1kg;5kg | Molecular Structure: | | Rivastigmine is one of the APIs for Parkinson's disease. |
|
|